Smoking: a Risk Factor for Pulmonary Arterial Hypertension?

Smoking: a Risk Factor for Pulmonary Arterial Hypertension? A D-A-CH Pulmonary Hypertension Study (Germany- Austria - Switzerland)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01484899

Acronym

DACH

Enrollment

500

Registered

2011-12-02

Start date

2011-09-30

Completion date

2012-12-31

Last updated

2013-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Hypertension

Keywords

Pulmonary arterial Hypertension, Chronic thromboembolic pulmonary hypertension, smoking

Brief summary

Environmental factors may play a role in the genesis of pulmonary hypertension, especially in endothelial dysfunction. One widespread environmental factor associated with systemic endothelial dysfunction is cigarette smoke. It may well be that cigarette smoking is not only a risk factor for systemic but also for pulmonary vascular diseases and herewith may interact with other risk factors such as a genetic background and associated conditions. The existing studies which deal with this subject are only small single center case control studies providing less data. Therefore a large European multicenter study is necessary. The investigators hypothesis are: * a history of tobacco smoke exposure is highly prevalent in patients with PAH compared to the unaffected general population. * a history of tobacco smoke exposure is more prevalent in patients with PAH compared to CTEPH.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* pulmonary artery pressure \>25mmHg * pulmonary capillary occlusion pressure ≤15mmHg

Exclusion criteria

* pulmonary artery pressure \<25mmHg * pulmonary capillary occlusion pressure \>15mmHg

Design outcomes

Primary

Measure	Time frame	Description
Difference in Prevalence of Smoking history in patients with PAH compared to unaffected general population	Assessment during outpatient consultation, an expected average of 1 day.	Patients will be asked with a specific questionnaire concerning their tobacco smoke exposure and smoking history. Control-group: Data from Swiss health survey (SHS) 2007 (Gesundheitsbefragung Schweiz).

Countries

Austria, Germany, Switzerland

Outcome results